Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADAG Adagene

Market Closed 11-13 16:00:00 EST

1.71

-0.29

-14.50%

盘后1.70

-0.01-0.58%

19:56 EST

High1.98	Low1.70	Vol152.06K
Open1.98	D1 Closing2.00	Amplitude14.00%
Mkt Cap114.82M	Tradable Cap76.66M	Total Shares67.14M
T/O273.61K	T/O Rate0.34%	Tradable Shares44.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADAG","market":"US","secType":"STK","nameCN":"Adagene","latestPrice":1.71,"timestamp":1794603600000,"preClose":2,"halted":0,"volume":152058,"hourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.71,"latestTime":"19:56 EST","volume":456,"amount":775.28,"timestamp":1794617769711,"change":-0.01,"changeRate":-0.005848,"amplitude":0.005848},"delay":0,"changeRate":-0.14500000000000002,"floatShares":44828200,"shares":67143300,"eps":-0.3773,"marketStatus":"Market Closed","change":-0.29,"latestTime":"11-13 16:00:00 EST","open":1.98,"high":1.98,"low":1.7,"amount":273611.0059764,"amplitude":0.14,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.3773,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"adrRate":1.25,"listingDate":1612846800000,"exchange":"NASDAQ","adjPreClose":2,"postHourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.71,"latestTime":"19:56 EST","volume":456,"amount":775.28,"timestamp":1794617769711,"change":-0.01,"changeRate":-0.005848,"amplitude":0.005848},"volumeRatio":0.8130264226338757},"requestUrl":"/m/hq/s/ADAG/tweets","defaultTab":"tweets","newsList":[{"id":"2682882723","title":"Adagene completes enrollment in muzastotug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2682882723","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682882723?lang=en_us&edition=fundamental","pubTime":"2026-11-09 20:38","pubTimestamp":1794227915,"startTime":"0","endTime":"0","summary":"Adagene (ADAG) announced completion of enrollment in its randomized Phase 2 dose-optimization trial of muzastotug, a masked, anti-CTLA-4 SAFEbody, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagene-completes-enrollment-in-muzastotug-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagene-completes-enrollment-in-muzastotug-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682807230","title":"Adagene Completes Enrollment in Phase 2 Trial of Muzastotug-Keytruda Combination for Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2682807230","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682807230?lang=en_us&edition=fundamental","pubTime":"2026-11-09 20:04","pubTimestamp":1794225892,"startTime":"0","endTime":"0","summary":"Adagene Completes Enrollment in Phase 2 Trial of Muzastotug-Keytruda Combination for Colorectal CancerAdagene completed enrollment of 60 patients in a randomized Phase 2 trial of muzastotug combined w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nNDL63xvK3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682005378","title":"Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2682005378","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682005378?lang=en_us&edition=fundamental","pubTime":"2026-11-09 20:00","pubTimestamp":1794225600,"startTime":"0","endTime":"0","summary":"- Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial- Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/09/3398256/0/en/adagene-announces-completion-of-enrollment-in-randomized-dose-optimization-phase-2-trial-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-microsatellite-stable-colorecta.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7061","BK4139","CRC","BK4195","ORR","PFS","SOC","BK4211","BBC","ADAG","BK4113","MSS","BK7095","SOC.AU","LU0456854461.SGD","LU0266512127.USD","ORR.AU","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678469419","title":"Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2678469419","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678469419?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185200,"startTime":"0","endTime":"0","summary":"Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver metasta","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/28/3390033/0/en/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-with-incyte-s-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSS","BK4550","IDNA","LU0266512127.USD","BK4532","ADAG","CRC","BK4113","LU0456854461.SGD","BK4588","BK4585","INCY","BK4213","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678179820","title":"Adagene Participates in Guggenheim Securities Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2678179820","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678179820?lang=en_us&edition=fundamental","pubTime":"2026-10-27 19:10","pubTimestamp":1793099450,"startTime":"0","endTime":"0","summary":"Adagene Participates in Guggenheim Securities Healthcare Innovation ConferenceAdagene will attend the Guggenheim Securities 3rd Annual Healthcare Innovation Conference in Boston, Nov. 9-11, 2026.Senio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDL6kM39Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014039.USD","BK4585","LU2210150020.SGD","ADAG","BK4588","NDAQ","IE00B3QW5Z07.USD","BCDF","IE00BGHQF748.EUR","IE00BQXX3F31.USD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU2095319765.USD","BK4112","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014021.USD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676507667","title":"Adagene Price Target Maintained with a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2676507667","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676507667?lang=en_us&edition=fundamental","pubTime":"2026-10-19 18:27","pubTimestamp":1792405620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAG/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675341555","title":"Adagene CEO Peter Luo Joins H.C. Wainwright Immune Cell Engager Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2675341555","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675341555?lang=en_us&edition=fundamental","pubTime":"2026-10-14 20:04","pubTimestamp":1791979449,"startTime":"0","endTime":"0","summary":"Adagene CEO Peter Luo joins H.C. Wainwright immune cell engager conference fireside chatAdagene will join the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference on Oct. 15, 2026.CEO Pet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nNDL66lJ5x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4588","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","IE00BQXX3D17.EUR","LU2210149790.SGD","LU0314104364.USD","LU2095319765.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","ADAG","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4139","BK4585","SG9999014039.USD","NDAQ","SG9999014005.SGD","IE00BKPKM429.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675415643","title":"Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2675415643","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675415643?lang=en_us&edition=fundamental","pubTime":"2026-10-14 20:00","pubTimestamp":1791979200,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, Oct.  14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/14/3380678/0/en/adagene-to-participate-in-h-c-wainwright-4th-annual-immune-cell-engager-virtual-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456854461.SGD","BK4139","CRC","BK4213","MSS","BK4113","LU0266512127.USD","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671168852","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Adagene (ADAG) and Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671168852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671168852?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:50","pubTimestamp":1790679012,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF), Adagene (ADAG) and Inven...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-roche-holding-ag-otherrhhvf-adagene-adag-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-roche-holding-ag-otherrhhvf-adagene-adag-and-inventiva-iva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG","BK4588","IVA","BK4581","HCSG","RHHVF","LABU","BK4007","BK4585","XLV","LU0128526141.USD","LU2539964713.USD","LU1046234339.USD","LU2293690249.USD","BK4139","BK4137","LU2293690082.USD","XBI","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670928422","title":"Adagene Announces Finance Executive Resignation Effective September 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2670928422","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670928422?lang=en_us&edition=fundamental","pubTime":"2026-09-26 05:01","pubTimestamp":1790370067,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Adagene ( ($ADAG) ). On September 30, 2026, Adagene Inc. announced that Ms. Chunfang (Vicky) Gu resigned from h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adagene-announces-finance-executive-resignation-effective-september-30-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adagene-announces-finance-executive-resignation-effective-september-30-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142557","title":"Adagene to Begin Phase 1 Study of Adg138 for Advanced Solid Tumors in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142557","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142557?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:52","pubTimestamp":1790081527,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Adagene Inc. <978y.F>::*ADAGENE ANNOUNCES NMPA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ADG138, A NOVEL HER2XCD3 DOUBLE-MASKED BISPECIFIC T-CELL ENGAGER*ADAGENE - TO B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSDcvMZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144262","title":"Adagene Wins NMPA IND Clearance for Novel HER2xCD3 T-Cell Engager ADG138","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144262","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144262?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:27","pubTimestamp":1790080070,"startTime":"0","endTime":"0","summary":"Adagene ( ($ADAG) ) has issued an announcement. Adagene Inc., a platform-driven, clinical-stage biotechnology company listed on Nasdaq, specializes...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adagene-wins-nmpa-ind-clearance-for-novel-her2xcd3-t-cell-engager-adg138?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adagene-wins-nmpa-ind-clearance-for-novel-her2xcd3-t-cell-engager-adg138?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","XT","BK4588","BK4139","BK4585","BBC","LNGR","DARP","BBP","AGNG","JDOC","LCLG","NQmain","SYNB","FHLC","RSPH","IBB","ADAG","FWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142880","title":"Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142880","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142880?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078400,"startTime":"0","endTime":"0","summary":"Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary S","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366259/0/en/adagene-announces-nmpa-clearance-of-investigational-new-drug-application-for-adg138-a-novel-her2xcd3-double-masked-bispecific-t-cell-engager.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0456854461.SGD","BK4213","LU0266512127.USD","CRC","BK4113","ADAG","MSS","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668891917","title":"Adagene CEO Makes Bold Insider Move With Fresh Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2668891917","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668891917?lang=en_us&edition=fundamental","pubTime":"2026-09-18 10:05","pubTimestamp":1789697128,"startTime":"0","endTime":"0","summary":"New insider activity at Adagene ( ($ADAG) ) has taken place on September 17, 2026. Adagene’s CEO, Peter Luo, has shown confidence in the company by...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/adagene-ceo-makes-bold-insider-move-with-fresh-stock-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/adagene-ceo-makes-bold-insider-move-with-fresh-stock-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668652349","title":"Adagene CEO Peter Luo Buys 20,290 ADS Worth $63,974.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2668652349","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668652349?lang=en_us&edition=fundamental","pubTime":"2026-09-17 18:12","pubTimestamp":1789639934,"startTime":"0","endTime":"0","summary":"Adagene CEO Peter Luo buys 20,290 ADS worth $63,974.40Adagene CEO Peter Luo bought 20,290 American Depositary Shares at an average price of USD 3.15.Directly held ADS position rose to 88,535 shares fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL72yhQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Adagene CEO Peter Luo Buys 20,290 ADS Worth $63,974.40","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668557","title":"Adagene Price Target Maintained with a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668557?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:03","pubTimestamp":1789383780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAG/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666216595","title":"Analysts’ Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666216595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666216595?lang=en_us&edition=fundamental","pubTime":"2026-09-11 19:40","pubTimestamp":1789126806,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adagene (ADAG), AbbVie (ABBV) and Definium Therapeut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-adagene-adag-abbvie-abbv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-adagene-adag-abbvie-abbv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B42XCP33.USD","TRUH","IE0009355771.USD","LU1061106388.HKD","LU1923622614.USD","LU0661504455.SGD","LU1732799900.SGD","LU1983299246.USD","HCSG","IE0002270589.USD","GLAM","LU1074936037.SGD","LU0708994859.HKD","LU0820561818.USD","LU1496350502.SGD","LU1057294990.SGD","LU0795875169.SGD","ABBV","JDOC","IE00B2B36J28.USD","VHT","LU1037948897.HKD","IXJ","IE0004445239.USD","LU0726765562.USD","LU0098860793.USD","LU2125909247.SGD","ADAG","LU0417517546.SGD","SG9999011175.SGD","LU0689626769.HKD","LU2023251221.USD","MEDX","RXL","LABU","LU0289739699.SGD","AGNG","XBI","IYH","FTXH","FHLC","LU2347655073.USD","LU2433249047.HKD","XLV","IE00BFTCPJ56.SGD","BK4559","IE0002141913.USD","LU1934455863.HKD","PPH","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666594701","title":"Adagene’s Platform Partnerships and Muzastotug Catalysts Support Buy Rating, Price Target Unchanged at $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666594701?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:05","pubTimestamp":1789052723,"startTime":"0","endTime":"0","summary":"Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Adagene. The associated price target remains the same with $8.00. Charle...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adagenes-platform-partnerships-and-muzastotug-catalysts-support-buy-rating-price-target-unchanged-at-8-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adagenes-platform-partnerships-and-muzastotug-catalysts-support-buy-rating-price-target-unchanged-at-8-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666759800","title":"Adagene, Third Arc Bio Expand SAFEbody Masked CD3 T-Cell Engager Collaboration with First Lead Pick","url":"https://stock-news.laohu8.com/highlight/detail?id=2666759800","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666759800?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:04","pubTimestamp":1789041845,"startTime":"0","endTime":"0","summary":"Adagene, Third Arc Bio expand SAFEbody masked CD3 T-cell engager collaboration with first lead pickAdagene broadened its strategic licensing collaboration with Third Arc Bio after Third Arc selected t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDLbVgK8M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666359817","title":"Adagene Initiated at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2666359817","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666359817?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:57","pubTimestamp":1789041420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAG/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.145},{"period":"1month","weight":-0.2533},{"period":"3month","weight":-0.5378},{"period":"6month","weight":-0.5114},{"period":"1year","weight":-0.05},{"period":"ytd","weight":-0.0952}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Their platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity. These features enable their novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. They have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Their platform is designed to enable the rapid development of precision immunotherapy candidates, through the identification of predictive biomarkers for patient stratification and preselection.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.330237},{"month":2,"riseRate":0.4,"avgChangeRate":-0.074707},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.132812},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.082401},{"month":5,"riseRate":0.666667,"avgChangeRate":0.056675},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.004737},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.062128},{"month":8,"riseRate":0.5,"avgChangeRate":0.001506},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.078426},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.111028},{"month":11,"riseRate":0.5,"avgChangeRate":-0.024564},{"month":12,"riseRate":0.4,"avgChangeRate":0.020923}],"exchange":"NASDAQ","name":"Adagene","nameEN":"Adagene","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adagene(ADAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adagene,ADAG,Adagene股票,Adagene股票老虎,Adagene股票老虎国际,Adagene行情,Adagene股票行情,Adagene股价,Adagene股市,Adagene股票价格,Adagene股票交易,Adagene股票购买,Adagene股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adagene(ADAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}